666 related articles for article (PubMed ID: 15155140)
1. Histone modification enzymes: novel targets for cancer drugs.
Kristeleit R; Stimson L; Workman P; Aherne W
Expert Opin Emerg Drugs; 2004 May; 9(1):135-54. PubMed ID: 15155140
[TBL] [Abstract][Full Text] [Related]
2. Small molecule modulators in epigenetics: implications in gene expression and therapeutics.
Swaminathan V; Reddy BA; Ruthrotha Selvi B; Sukanya MS; Kundu TK
Subcell Biochem; 2007; 41():397-428. PubMed ID: 17484138
[TBL] [Abstract][Full Text] [Related]
3. Inducible covalent posttranslational modification of histone H3.
Bode AM; Dong Z
Sci STKE; 2005 Apr; 2005(281):re4. PubMed ID: 15855410
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylases and cancer: causes and therapies.
Marks P; Rifkind RA; Richon VM; Breslow R; Miller T; Kelly WK
Nat Rev Cancer; 2001 Dec; 1(3):194-202. PubMed ID: 11902574
[TBL] [Abstract][Full Text] [Related]
5. Histone modifying enzymes and cancer: going beyond histones.
Zhang K; Dent SY
J Cell Biochem; 2005 Dec; 96(6):1137-48. PubMed ID: 16173079
[TBL] [Abstract][Full Text] [Related]
6. Histone acetylation and methylation: combinatorial players for transcriptional regulation.
An W
Subcell Biochem; 2007; 41():351-69. PubMed ID: 17484136
[TBL] [Abstract][Full Text] [Related]
7. Histone acetylation in gene regulation.
Verdone L; Agricola E; Caserta M; Di Mauro E
Brief Funct Genomic Proteomic; 2006 Sep; 5(3):209-21. PubMed ID: 16877467
[TBL] [Abstract][Full Text] [Related]
8. Histone post-translational modification: from discovery to the clinic.
Thomas NR
IDrugs; 2006 Jun; 9(6):398-401. PubMed ID: 16752306
[No Abstract] [Full Text] [Related]
9. Histone deacetylase inhibitors.
Marks PA; Richon VM; Miller T; Kelly WK
Adv Cancer Res; 2004; 91():137-68. PubMed ID: 15327890
[TBL] [Abstract][Full Text] [Related]
10. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
Mai A; Altucci L
Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
12. Acetylation of proteins as novel target for antitumor therapy: review article.
Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
[TBL] [Abstract][Full Text] [Related]
13. Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes.
Gibbons RJ
Hum Mol Genet; 2005 Apr; 14 Spec No 1():R85-92. PubMed ID: 15809277
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic control of ovarian function: the emerging role of histone modifications.
LaVoie HA
Mol Cell Endocrinol; 2005 Nov; 243(1-2):12-8. PubMed ID: 16219412
[TBL] [Abstract][Full Text] [Related]
15. Regulation and regulatory parameters of histone modifications.
Davie JR; Chadee DN
J Cell Biochem Suppl; 1998; 30-31():203-13. PubMed ID: 9893272
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
17. Simple histone acetylation plays a complex role in the regulation of gene expression.
Fukuda H; Sano N; Muto S; Horikoshi M
Brief Funct Genomic Proteomic; 2006 Sep; 5(3):190-208. PubMed ID: 16980317
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic transitions: towards therapeutic targets.
Kalebic T
Expert Opin Ther Targets; 2003 Dec; 7(6):693-9. PubMed ID: 14640906
[TBL] [Abstract][Full Text] [Related]
19. Regulation and function of H3K9 methylation.
Shinkai Y
Subcell Biochem; 2007; 41():337-50. PubMed ID: 17484135
[TBL] [Abstract][Full Text] [Related]
20. Chromatin modifications as targets for new anticancer drugs.
Schäfer S; Jung M
Arch Pharm (Weinheim); 2005 Aug; 338(8):347-57. PubMed ID: 16041839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
